PERSPECTIVE THERAPEUTICS INC (CATX) competitors & alternatives
Health Care · NYSE American
PERSPECTIVE THERAPEUTICS INC (CATX)'s top competitors and alternatives — its most similar public companies — include KURA ONCOLOGY INC (KURA), NURIX THERAPEUTICS INC (NRIX), FOGHORN THERAPEUTICS INC (FHTX), MONTE ROSA THERAPEUTICS INC (GLUE), CYTOMX THERAPEUTICS INC (CTMX), ORIC PHARMACEUTICALS INC (ORIC), MONOPAR THERAPEUTICS INC (MNPR), ASTRAZENECA PLC (AZN), CRISPR THERAPEUTICS AG (CRSP), AURA BIOSCIENCES INC (AURA), VOR BIOPHARMA INC (VOR) and ADC THERAPEUTICS SA (ADCT). These are PERSPECTIVE THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CATX competitors & alternatives
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
FOGHORN THERAPEUTICS INCFHTXHealth Care
Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal…
$5.21 (as of 2026-07-22) · market cap $306M
-
MONTE ROSA THERAPEUTICS INCGLUEHealth Care
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its…
$23.79 (as of 2026-07-22) · market cap $2.0B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
AURA BIOSCIENCES INCAURAHealth Care
Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving…
$7.01 (as of 2026-07-22) · market cap $725M
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
Not quite? Describe exactly what you want →
Peers are PERSPECTIVE THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PERSPECTIVE THERAPEUTICS INC (CATX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.